Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
1期
已完成
NCT03239145
| 适应症 | Advanced Solid Tumor |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Dana-Farber Cancer Institute |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 62 人 |
|---|
| 干预（药物） | Pembrolizumab, Trebananib |
|---|
| 开始日期 | 2018年5月1日 |
|---|
| 完成日期 | 2024年12月13日 |
|---|
| 结果公布日 | 2026年3月12日 |
|---|
摘要
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386
Number of Participants Experienced Dose Limit Toxicities (DLT)
3 weeks · Participants
| [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 Participants |
|---|
| [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 0 Participants |
|---|
Maximum Tolerated Dose (MTD) of Trebananib
3 weeks · mg/kg
| [Dose Escalation Dose Level I and Dose Level II] Pembrolizumab + Trebananib | 30 mg/kg |
|---|
Grade 3 or Higher Toxicity Rate in Expansion Cohort
The median follow up time was 3.3 months (range: 0.6 to 25.3 months). · percentage of participants
| [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 59.5 percentage of participants |
|---|
| Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 63.6 percentage of participants |
|---|
| Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 75.0 percentage of participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。